KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ClearPoint Neuro (CLPT) EBITDA Margin (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed EBITDA Margin for 13 consecutive years, with 67.68% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 19772.0% to 67.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 65.36% through Dec 2025, down 5264.0% year-over-year, with the annual reading at 65.36% for FY2025, 5264.0% down from the prior year.
  • EBITDA Margin hit 67.68% in Q4 2025 for ClearPoint Neuro, down from 59.54% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 130.05% in Q4 2024 to a low of 119.85% in Q2 2023.
  • Historically, EBITDA Margin has averaged 66.86% across 5 years, with a median of 73.19% in 2025.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 19915bps in 2024 and later plummeted -19772bps in 2025.
  • Year by year, EBITDA Margin stood at 92.99% in 2021, then grew by 7bps to 86.37% in 2022, then rose by 20bps to 69.1% in 2023, then soared by 288bps to 130.05% in 2024, then plummeted by -152bps to 67.68% in 2025.
  • Business Quant data shows EBITDA Margin for CLPT at 67.68% in Q4 2025, 59.54% in Q3 2025, and 61.64% in Q2 2025.